Baldo Scassellati Sforzolini
- Business Wire
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
– Upfront and approval payments of up to $15 million – Tiered royalties ranging from mid- to high-teen percentage of…
Read More » - Health
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure®/ Dysport® (abobotulinumtoxinA)
Lausanne, Switzerland: Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the…
Read More »